Gustave Roussy immune score as an independent prognostic factor for treatment response and survival in advanced renal cell carcinoma treated with nivolumab in second-line and beyond
The GRIm score effectively stratifies mRCC patients treated with nivolumab, identifying those with significantly better survival and treatment responses. As a simple, cost-effective tool, it offers potential for integration into clinical practice to guide personalized treatment strategies. Further prospective studies are warranted to validate these findings.
Authors
- Muhammet Bekir Hacıoğlu (ORCID: https://orcid.org/0000-0001-8490-3239)
- İsmail Bayrakçı (ORCID: https://orcid.org/0000-0002-5785-8273)
- Hilmi Kodaz
- İlhan Hacıbekiroğlu (ORCID: https://orcid.org/0000-0002-0333-7405)
- Didem Divriklioğlu (ORCID: https://orcid.org/0000-0001-9956-3900)
- İvo Gökmen (ORCID: https://orcid.org/0000-0002-0382-5396)
- Erkan Özcan (ORCID: https://orcid.org/0000-0002-5633-9359)
- Bülent Erdoğan (ORCID: https://orcid.org/0000-0002-9848-2700)
- Ahmet Küçükarda (ORCID: https://orcid.org/0000-0001-7399-2360)
- Cagnur Elpen Kodaz
- Esra Özen Engin (ORCID: https://orcid.org/0000-0002-5225-1456)
- Gökhan Öztürk (ORCID: https://orcid.org/0000-0002-6353-5825)
Institutions
- Sakarya University (TR)
- Trakya University (TR)
- Bilecik Şeyh Edebali Üniversitesi (TR)
- Eskişehir City Hospital (TR)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-16
- DOI
- https://doi.org/10.3389/fonc.2025.1657053
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52